35 FDA-Approved Drugs in 2011: Key Innovations in Medication

The Year 2011: A Timeline of Pharmaceutical Advances

Welcome to the advancement timeline of 2011. 2011 was a significant year for the FDA, with 35 new drugs being approved that year. This year marked notable innovations in medication, often targeting previously unmet medical needs and enhancing the therapeutic options available to patients. Below, we explore some of the most notable approved drugs in 2011, classified as Priority and Standard drugs by the FDA.

Priority Drugs

Adcetris (Brentuximab Vedotin) - This cancer drug targets Hodgkin and other lymphomas, expanding treatment options for patients with advanced or refractory conditions. Anascro (Inotersen) - Anascro received approval for treating familial amyloid polyneuropathy, a rare and progressive disease affecting the nervous system. Benlysta (Belimumab) - The first FDA-approved drug for systemic lupus erythematosus (SLE), marking a significant breakthrough in the treatment of this autoimmune disorder. Caprelsa (Cabozantinib) - Caprelsa is used to treat advanced kidney cancer and thyroid cancer, enhancing the quality of life for patients with these diseases. Corifact (Celixantin) - Corifact, an antihemophilic factor (Recombinant) PF4/ProTHram, is effective in treating bleeding episodes in people with hemophilia A. DaTscan (Florbetapir) - This imaging agent is used to diagnose Parkinson's-related dementia, providing a tool for early and accurate diagnosis. Dificid (Furazolidone) - Dificid addresses the increasing problem of antibiotic resistance by treating Clostridium difficile infections, a significant concern in healthcare settings. Firazyr (Icatibant) - Firazyr offers a new approach for recurrent hereditary angioedema, a rare but serious condition involving painful swelling. Halaven (Ebindingslobulin) - Halaven is a treatment for metastatic breast cancer, offering a promising new option for women facing this challenging condition. Incivek (Telaprevir) - Available for hepatitis C, Incivek represents a significant advancement in hepatitis C treatment, streamlining the therapy process for many patients. Pradaxa (Dabigatran etexilate mesylate) - Pradaxa is used to prevent stroke and systemic embolism in patients with atrial fibrillation, an advancement in heart disease management. Victrelis (Lansoprazole inatasotide) - Victrelis treats chronic hepatitis C, another major leap in the treatment of this viral infection. Xalkori (Crizotinib) - Xalkori addresses advanced non-small cell lung cancer, enhancing treatment options for those with oncogenic alterations. Zelboraf (Vemurafenib) - Zelboraf, the first targeted therapy for melanoma, is a milestone in cancer treatment, targeting a specific genetic mutation.

Standard Drugs

Acapta Neohaler (Indacaterol Maleate) - Standard treatments for asthma and chronic obstructive pulmonary disease (COPD). Ardovax (Avac unleash) - Used for bacterial pneumonia, arдовax in treating acute respiratory infections. Brilinta (Tirofiban Hydrochloride) - Brilinta manages platelet aggregation, improving outcomes in patients who have had a heart attack or are at risk of one. Daliresp (Romiplostim) - Daliresp helps increase platelet counts in patients with aplastic anemia, a rare and serious blood disorder. Edaravone (Edaravone) - Edaravone addresses cerebral infarction, providing a new option for stroke recovery. Edurant (Tenofovir alafenamide) - Used to treat HIV, Edurant improves the tolerance of the drug compared to its predecessors. Egrifta (Pararicaprozess) - Egrifta is used to reduce fat in the abdomen in people with lipodystrophy. Horizant (Guanfacine Extended-Release Tablets) - Horizant is used to treat the symptoms of Restless Legs Syndrome, a condition causing an uncontrollable urge to move the legs. Latuda (Lurasidone Hydrochloride) - Latuda is used to treat bipolar disorder and schizophrenia, expanding the options available to mental health patients.LaViv (L-malate, stereoisomer-1) - LaViv treats certain types of lymphoma, providing an alternative treatment method. Natroban (Flumazenil) - Natroban is used to reverse the effects of certain benzodiazepine sedatives, aiding in emergency care. Nulojix (Cediranib) - This antiangiogenic drug is used to treat kidney cancer and gastrointestinal stromal tumors (GIST), targeting cancer growth and development. Potiga (Prioglitazone) - Potiga is used for treating trigeminal neuralgia, a painful neurological disorder. Spherusol (S-Phenytoin) - Spherusol is an anticonvulsant drug used to prevent and control seizures in epilepsy. Teflaro (Tequin) - Teflaro addresses infections caused by resistant bacteria, offering a new weapon in the fight against antibiotic resistance. Tradjenta (Linagliptin) - Trajenta is used to lower blood sugar in type 2 diabetes, a new and effective medication for diabetes management. Viibryd (Vortioxetine) - Viibryd is a new medication for depression, featuring fewer side effects compared to older antidepressants. Xarelto (Rivaroxabin) - Xarelto helps prevent blood clots, filling a gap in anticoagulants and offering a new option for preventing deep vein thrombosis and pulmonary embolism.

Conclusion on the Year 2011 in Pharmaceutical Innovations

2011 was a remarkable year for the pharmaceutical industry, with the FDA approving 35 drugs that demonstrated significant improvements over existing treatments. The array of new drugs showcased innovation across various therapeutic areas, ranging from cancer and rare diseases to cardiovascular health and mental health. This array of new medicines brought hope and potentially life-changing benefits to patients in need. As we continue to witness the progress of medical science and drug development, the coming years promise even more breakthroughs in healthcare.

For further reading and statistics regarding the FDA's approval of new drugs, refer to the official FDA documents available via http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Reports/UCM278358.pdf.